Abstract
The Bayesian Ordered Lattice Design (BOLD) method for Phase I clinical trials is extended to address an important challenge. It is widely understood that conventional Phase I trial designs are not consistently effective in determining safe and active dose levels. The US FDA launched the Project Optimus, aimed at reforming the paradigms of dose optimization and selection. We propose a backfill BOLD design (BF-BOLD) that centers on BOLD for dose-finding but also adds an activity evaluation for each patient. Our method for determining the optimal biological dose (OBD) first involves identifying the maximum tolerated dose (MTD) and then assessing activity rates among dose levels below the identified MTD. This approach is straight-forward and does not require complex statistical modeling. The results of the simulation indicate that performing dose-finding trials with backfilling can both enhance safety and activity assessment, thereby improving treatment sustainability while also preserving the potential for efficacy of the Recommended Phase II Dose (RP2D). We also demonstrate the applicability of the backfill design for reducing overdose rates, and as a more attractive alternative to small-scale dose expansion trials that follow dose escalation. Backfill designs are an important design approach for early phase trials.
Full Text Availability
The license terms selected by the author(s) for this preprint version do not permit archiving in PMC. The full text is available from the preprint server.
